Fidaxomicin
Pre-clinicalWithdrawn 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection (CDI)
Conditions
Clostridium Difficile Infection (CDI)
Trial Timeline
Aug 1, 2019 → May 1, 2023
NCT ID
NCT04070352About Fidaxomicin
Fidaxomicin is a pre-clinical stage product being developed by Merck for Clostridium Difficile Infection (CDI). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04070352. Target conditions include Clostridium Difficile Infection (CDI).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04070352 | Pre-clinical | Withdrawn |
| NCT01591863 | Phase 2 | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection (CDI)